Cutera® Announces Third Quarter 2024 Financial Results

Rhea-AI Summary

Cutera (CUTR) reported Q3 2024 financial results with consolidated revenue of $32.5 million, representing a 30% decrease compared to Q3 2023. The company maintained cash and equivalents of $59.0 million. AviClear showed 16% growth year-over-year in international markets, while global core capital grew 7% sequentially. Gross profit was $1.8 million (6% of revenue), down from $6.5 million (14%) in Q3 2023. Operating loss was $36.2 million. Management reaffirmed full-year revenue guidance of $140-145 million and year-end 2024 cash guidance of approximately $40 million.

Positive

• AviClear revenue growth of 16% year-over-year in international markets
• Global core capital growth of 7% quarter-over-quarter
• Management maintains full-year revenue guidance of $140-145 million

Negative

• Revenue decreased 30% year-over-year to $32.5 million
• Gross profit margin declined to 6% from 14% in Q3 2023
• Operating loss of $36.2 million in Q3 2024
• $10.1 million non-cash expense for excess inventory
• Cash position decreased from $84.3M to $59.0M quarter-over-quarter

Insights

Financial Analyst

The Q3 results reveal significant challenges at Cutera, with $32.5M revenue marking a 30% YoY decline. The company's financial health shows concerning trends with gross margin deteriorating to just 6% from 14% YoY. A substantial $10.1M non-cash inventory charge and $5.4M doubtful accounts receivable expense signal operational difficulties. Cash position declined from $84.3M to $59M QoQ, indicating rapid cash burn. While management maintains full-year guidance of $140-145M revenue, the 17% decline in capital system sales and 19% drop in recurring revenue (ex-skincare) suggest structural business challenges beyond just the loss of skincare revenue.

Market Research Analyst

The medical aesthetics market dynamics appear challenging for Cutera, with core metrics showing weakness. While AviClear showed 16% growth internationally, domestic market penetration seems The 7% sequential growth in global core capital, while positive, isn't sufficient to offset broader revenue declines. The termination of the skincare distribution agreement has created a significant revenue gap that core business growth hasn't filled. The high inventory charges suggest misalignment with market demand, while the substantial doubtful accounts provision indicates potential customer financial stress or collection issues.

BRISBANE, Calif.--(BUSINESS WIRE)-- CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the third quarter ended September 30, 2024.

• Consolidated revenue for the third quarter of 2024 of $32.5 million
• Cash, cash equivalents, and restricted cash of $59.0 million
• AviClear growth of 16% vs prior year period driven by international capital system sales
• Global core capital growth of 7% on a sequential quarterly basis
• Full-year guidance maintained for both revenue and year-end cash balance

“Our third quarter reflects consistent execution against our strategic priorities, with core capital sales improving on a sequential basis, AviClear continuing to grow year-over-year driven by strong sales and utilization in international markets, and favorable underlying trends in our gross margin and operating expense profile,” commented Taylor Harris, Chief Executive Officer of Cutera, Inc. “We remain focused on expanding access to AviClear, our breakthrough technology for the treatment of acne, through training and education, practice development, and clinical indication expansion.”

Third Quarter 2024 Financial Highlights

Consolidated revenue for the third quarter of 2024 was $32.5 million, a decrease of 30% compared to the third quarter 2023. Revenue in the third quarter of 2023 included skincare revenue of $7.1 million; following the termination of our skincare distribution agreement in February 2024, the third quarter of 2024 did not include skincare revenue. Revenue related to capital systems sales declined 17%, while recurring sources of revenue, excluding skincare, declined 19%.

Gross profit was $1.8 million, or 6% of revenue for the third quarter of 2024, compared to a gross profit of $6.5 million, or 14% of revenue, for the third quarter of 2023. On a non-GAAP basis, gross profit was $3.7 million, or 12% of revenue, for the third quarter of 2024, compared to $9.0 million, or 19%, for the third quarter of 2023. Gross profit in the third quarter, on a GAAP and a non-GAAP basis, was negatively affected by $10.1 million, or 31% of revenue, of non-cash expense related to excess and obsolete inventory.

Operating expenses were $38.0 million for the third quarter of 2024, compared to $47.4 million in the prior year period. On a non-GAAP basis, operating expenses were $34.7 million for the third quarter of 2024, compared to $39.8 million for the prior year period. Operating expenses for the third quarter of 2024, on a GAAP and non-GAAP basis, include a $5.4 million charge related to doubtful accounts receivable. The Company no longer adjusts for costs related to a retention plan implemented in April 2023, in its Reconciliation of Non-GAAP Financial Measures. Accordingly, the Company has not adjusted for $0.4 million of retention plan costs incurred in the third quarter of 2024. Further, the Company has revised the presentation of current and prior year periods to remove adjustments related to retention plan costs of $4.0 million for the nine months ending September 30, 2024, and $1.4 million and $4.3 million, in the three and nine months ended September 30, 2023, respectively.

GAAP operating loss was $36.2 million and $40.9 million for the third quarters of 2024 and 2023, respectively. Non-GAAP operating loss was $31.0 million for the third quarter of 2024, compared to a Non-GAAP operating loss of $30.9 million for the third quarter of 2023.

Cash, cash equivalents, and restricted cash, were $59.0 million as of September 30, 2024, compared to $84.3 million as of June 30, 2024.

2024 Outlook

Management is reaffirming full-year revenue guidance of $140 million to $145 million, as well as guidance for year-end 2024 cash, cash equivalents and restricted cash of approximately $40 million.

Conference Call

The Company’s management will host a conference call to discuss these results and related matters today at 1:30 p.m. PT (4:30 p.m. ET). Participating in the call will be Taylor Harris, Chief Executive Officer, Stuart Drummond, Interim Chief Financial Officer, and Shelby Eckerman, Vice President, Finance.

Participants can register for the conference call at this registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remain open until the end of the live conference call.

If participants prefer to dial in and speak with an operator, dial Canada/USA Toll Free: 1-844-763-8274 or +1-647-484-8814. It is recommended that you call in 10 minutes prior to the scheduled start time if you are using one of these operator-assisted phone numbers.

The call will also be webcast and can be accessed from the Investor Relations section of Cutera’s website at http://www.cutera.com/. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

About Cutera, Inc.

Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. For over 25 years, Cutera has strived to improve lives through medical aesthetic technologies that are driven by science and powered through partnerships. For more information, call 1-888-4-CUTERA or visit Cutera.com.

*Use of Non-GAAP Financial Measures

In this press release, to supplement the Company’s condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles (“GAAP”), management has disclosed certain non-GAAP financial measures for gross profit, gross margin rate, and income or loss from operations. Non-GAAP adjustments include depreciation and amortization including contract acquisition costs, stock-based compensation, enterprise resource planning (“ERP”) implementation costs, certain legal and litigation costs, costs associated with restructuring activities and the separation of its officers and other executives, gain on termination of a distribution agreement, and certain other adjustments. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to investors and management. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure.

The Company defines non-GAAP operating income (loss), also commonly known as adjusted EBITDA, as operating income (loss) before depreciation and amortization, stock-based compensation, ERP implementation costs, certain legal and litigation costs, severance, gain on early termination of distribution agreement, and other adjustments.

Company management uses non-GAAP financial measures as aids in monitoring the Company’s ongoing financial performance from quarter to quarter, and year to year, and for benchmarking against other similar companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, the operating performance measure as prescribed by GAAP. Non-GAAP financial measures for the statement of operations and net income per share exclude the following:

Depreciation and amortization, including contract acquisition costs. The Company has excluded depreciation and amortization expense in calculating its non-GAAP operating expenses and net income measures. Depreciation and amortization are non-cash charges to current operations;

Stock-based compensation. The Company has excluded the effect of stock-based compensation expenses in calculating its non-GAAP operating expenses and net income measures. Although stock-based compensation is a key incentive offered to the Company's employees, the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expenses related to grants of options, employee stock purchase plans, and performance and restricted stock. Depending upon the size, timing, and terms of the grants, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation better allows for comparisons to its peer companies;

ERP implementation costs. The Company has excluded ERP system costs related to direct and incremental costs incurred in connection with its multi-phase implementation of a new ERP solution and the related technology infrastructure costs. The Company excludes these costs because it believes that these items do not reflect future operating expenses and will be inconsistent in amounts and frequency, making it difficult to contribute to a meaningful evaluation of the Company’s operating performance;

Certain legal and litigation costs. The Company has excluded costs incurred related to its litigation against Lutronic Aesthetics as well as the settlement of $5.8 million, which is not part of the Company’s ordinary course of business. The Company’s complaint against Lutronic alleged misappropriation of trade secrets, violation of the Racketeer Influenced and Corrupt Organizations Act (“RICO”), interference with contractual relations and other claims. The Company excludes these costs as well as the settlement because this litigation is a result of a discrete event that was not part of the Company’s business strategy, but has a significant effect on the results of operations. The costs are incidental to and do not reflect the efficiencies and effectiveness of the Company’s core operations;

Severance. The Company has excluded costs associated with restructuring activities and the separation of its officers and other executives in calculating its non-GAAP operating expenses and non-GAAP Operating Income. The Company has excluded restructuring costs because a restructuring represents a discrete event that signifies a change in the Company’s strategy, but these costs are not indicative of the ongoing financial performance of the business. The Company excludes executive separation costs because executive separations are unpredictable and not part of the Company’s business strategy but could have a significant impact on the results of operations;

Gain on early termination of distribution agreement. The Company has excluded a gain recorded in connection with the early termination of a distribution agreement with ZO USA in calculating its non-GAAP operating expenses and non-GAAP operating income (loss). The Company recorded the net gain of $9.7 million in the Company's condensed consolidated statement of operations for the three months ended March 31, 2024. The Company has excluded this gain as it is not indicative of the ongoing financial performance of the business, and not part of the Company’s business strategy.

The Company believes that excluding all of the items above allows users of its financial statements to better review and assess both current and historical results of operations. The Company no longer adjusts for costs related to a retention plan implemented in April 2023, as such costs represent a normal, recurring, operating cost, and accordingly, has not adjusted for $0.4 million of retention plan costs incurred in the third quarter of 2024. Further, the Company has revised the presentation of the prior year periods to remove adjustments for retention plan costs of $1.4 million and $4.3 million, in the three and nine months ended September 30, 2023, respectively.

Safe Harbor Statement

Certain statements in this press release, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements include but are not limited to express or implied statements regarding expanding access to AviClear, and full year revenues and cash, cash equivalents and restricted cash, along with other express or implied statements regarding Cutera’s plans, objectives, strategies, financial performance, guidance and outlook, product launches and performance, trends, prospects, or future events. In some cases, you can identify forward-looking statements by the use of words such as, but not limited to, “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee” or variations of these terms and similar expressions or the negative of these terms or similar expressions. Forward-looking statements are based on management's current expectations and beliefs and are subject to risks and uncertainties, which are difficult to predict and may cause Cutera's actual results to differ materially from the express or implied forward-looking statements herein. These forward-looking statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are several risks, uncertainties, and other important factors, many of which are beyond Cutera’s control, that could cause its actual results to differ materially from the forward-looking statements, including risks involved with continued expansion of AviClear, Cutera’s financial position and debt service requirements, and making financial projections, as well as the other risks described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other documents filed from time to time with the United States Securities and Exchange Commission by Cutera.

All statements made in this release are made only as of the date set forth at the beginning of this release. Accordingly, undue reliance should not be placed on forward-looking statements. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. If Cutera updates one or more forward-looking statements, no inference should be drawn that it will make additional updates concerning those or other forward-looking statements. Cutera's financial performance for the third quarter ended September 30, 2024, as discussed in this release, is preliminary and unaudited, and subject to adjustment.

CUTERA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
	September 30,				December 31,
	2024				2023
Assets
Current assets:
Cash and cash equivalents	$	57,614			$	143,612
Accounts receivable, net		33,150				43,121
Inventories		56,908				62,600
Other current assets and prepaid expenses		12,842				19,852
Total current assets		160,514				269,185
Long-term inventories		28,664				16,283
Property and equipment, net		23,521				37,275
Deferred tax asset		590				579
Restricted cash		1,363				-
Goodwill		1,339				1,339
Operating lease right-of-use assets		10,593				10,055
Other long-term assets		7,834				11,575
Total assets	$	234,418			$	346,291
Liabilities and Stockholders' Deficit
Current liabilities:
Accounts payable	$	7,949			$	19,829
Accrued liabilities		35,972				55,055
Operating leases liabilities		3,386				2,441
Deferred revenue		8,382				10,422
Total current liabilities		55,689				87,747
Deferred revenue, net of current portion		1,689				1,494
Operating lease liabilities, net of current portion		8,397				8,887
Convertible notes, net of unamortized debt issuance costs		420,422				418,695
Other long-term liabilities		1,095				1,298
Total liabilities		487,292				518,121
Stockholders’ deficit:
Common stock		20				20
Additional paid-in capital		136,929				131,496
Accumulated deficit		(389,823	)			(303,346	)
Total stockholders' deficit		(252,874	)			(171,830	)
Total liabilities and stockholders' deficit	$	234,418			$	346,291

CUTERA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
	Three Months Ended								Nine Months Ended
	September 30,				September 30,				September 30,				September 30,
	2024				2023				2024				2023
Products	$	27,242			$	40,989			$	88,714			$	146,285
Service		5,258				5,489				16,956				16,544
Total net revenue		32,500				46,478				105,670				162,829
Products		27,991				36,586				75,045				98,696
Service		2,696				3,435				8,749				9,961
Total cost of revenue		30,687				40,021				83,794				108,657
Gross profit		1,813				6,457				21,876				54,172
Gross margin %		5.6	%			13.9	%			20.7	%			33.3	%
Operating expenses:
Sales and marketing		18,928				25,808				63,269				88,591
Research and development		4,353				4,592				13,817				16,844
General and administrative		14,749				17,004				31,951				47,448
Gain on early termination of distribution agreement		-				-				(9,708	)			-
Total operating expenses		38,030				47,404				99,329				152,883
Loss from operations		(36,217	)			(40,947	)			(77,453	)			(98,711	)
Amortization of debt issuance costs		(580	)			(561	)			(1,726	)			(1,670	)
Interest expense on convertible notes		(3,071	)			(2,939	)			(8,969	)			(8,836	)
Interest income		768				2,288				3,248				6,946
Other expense (income), net		575				(1,948	)			(1,128	)			(2,564	)
Loss before income taxes		(38,525	)			(44,107	)			(86,028	)			(104,835	)
Income tax expense		493				167				449				765
Net loss	$	(39,018	)		$	(44,274	)		$	(86,477	)		$	(105,600	)
Net loss per share:
Basic	$	(1.94	)		$	(2.22	)		$	(4.31	)		$	(5.32	)
Diluted	$	(1.94	)		$	(2.22	)		$	(4.31	)		$	(5.32	)
Weighted-average number of shares used in per share calculations:
Basic		20,154				19,932				20,079				19,858
Diluted		20,154				19,932				20,079				19,858

CUTERA, INC.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in thousands, except percentage data)
(unaudited)
		Three Months Ended								% Change			Nine Months Ended								% Change
		September 30,				September 30,				2024 Vs			September 30,				September 30,				2024 Vs
		2024				2023				2023			2024				2023				2023
Revenue By Geography:
North America		$	14,651			$	24,855			-41.1	%		$	49,150			$	84,494			-41.8	%
Japan			3,420				11,529			-70.3	%			14,847				37,247			-60.1	%
Rest of World			14,429				10,094			+42.9	%			41,673				41,088			+1.4	%
Total Net Revenue		$	32,500			$	46,478			-30.1	%		$	105,670			$	162,829			-35.1	%
International as a percentage of total revenue			54.9	%			46.5	%						53.5	%			48.1	%
Revenue By Product Category:
Systems
- North America		$	9,253			$	16,982			-45.5	%		$	30,926			$	59,750			-48.2	%
- Rest of World (including Japan)			13,771				10,618			+29.7	%			40,258				41,654			-3.4	%
Total Systems			23,024				27,600			-16.6	%			71,184				101,404			-29.8	%
Consumables			4,218				6,248			-32.5	%			13,330				20,186			-34.0	%
Skincare			-				7,141			-100.0	%			4,200				24,695			-83.0	%
Total Products			27,242				40,989			-33.5	%			88,714				146,285			-39.4	%
Service			5,258				5,489			-4.2	%			16,956				16,544			+2.5	%
Total Net Revenue		$	32,500			$	46,478			-30.1	%		$	105,670			$	162,829			-35.1	%

CUTERA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
	Three Months Ended								Nine Months Ended
	September 30,				September 30,				September 30,				September 30,
	2024				2023				2024				2023
Cash flows from operating activities:
Net loss	$	(39,018	)		$	(44,274	)		$	(86,477	)		$	(105,600	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		1,841				1,616				5,543				6,552
Depreciation and amortization		1,669				1,987				5,464				5,225
Amortization of contract acquisition costs		1,113				3,016				3,882				7,085
Amortization of debt issuance costs		581				561				1,727				1,670
Deferred tax assets		(82	)			19				(11	)			62
Provision for credit losses		4,931				3,574				9,739				5,488
Accretion of discount on investment securities and investment income, net		-				902				-				1,048
Changes in assets and liabilities:
Accounts receivable		(3,402	)			276				232				(9,755	)
Inventories		11,841				2,317				3,259				1,781
Other current assets and prepaid expenses		118				5,128				7,010				4,352
Other long-term assets		(142	)			(860	)			(472	)			(5,642	)
Accounts payable		(9,668	)			(3,069	)			(11,880	)			(4,735	)
Accrued liabilities		5,737				(7,157	)			(18,704	)			(10,963	)
Operating leases ,net		(27	)			(14	)			(83	)			(44	)
Deferred revenue		(234	)			(899	)			(1,845	)			(390	)
Net cash used in operating activities		(24,742	)			(36,877	)			(82,616	)			(103,866	)
Cash flows from investing activities:
Acquisition of property and equipment		(173	)			(5,534	)			(1,390	)			(30,642	)
Proceeds from disposal of property and equipment		-				-				63				-
Proceeds from maturities of marketable investments		-				41,044								193,903
Purchases of marketable investments		-				-				-				(23,467	)
Net provided by (used in) cash used in investing activities		(173	)			35,510				(1,327	)			139,794
Cash flows from financing activities:
Proceeds from exercise of stock options and employee stock purchase plan		-				465				-				1,323
Taxes paid related to net share settlement of equity awards		(26	)			(87	)			(110	)			(3,273	)
Payments on finance lease obligation		(393	)			(149	)			(582	)			(386	)
Net cash provided by (used in) financing activities		(419	)			229				(692	)			(2,336	)
Net increase (decrease) in cash, cash equivalents and restricted cash		(25,334	)			(1,138	)			(84,635	)			33,592
Cash, cash equivalents, and restricted cash at beginning of period		84,311				181,354				143,612				146,624
Cash, cash equivalents, and restricted cash at end of period	$	58,977			$	180,216			$	58,977			$	180,216

CUTERA, INC.
Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measure
(in thousands)
Three Months Ended September 30, 2024		Gross Profit				Gross Margin			Operating Expenses			Operating Income
Reported		$	1,813			5.6	%		$	38,030		$	(36,217	)
Adjustments:
Depreciation and amortization including contract acquisition costs			1,643			5.1	%			1,138			2,781
Stock-based compensation			102			0.3	%			1,739			1,841
Legal - Lutronic settlement			-			0.0	%			-			-
Severance			189			0.6	%			454			643
Gain on early termination of distribution agreement			-			0.0	%			-			-
Other adjustments			-			0.0	%			-			-
Total adjustments			1,934			6.0	%			3,331			5,265
Non-GAAP		$	3,747			11.5	%		$	34,699		$	(30,952	)
Three Months Ended September 30, 2023		Gross Profit				Gross Margin			Operating Expenses			Operating Income
Reported		$	6,457			13.9	%		$	47,404		$	(40,947	)
Adjustments:
Depreciation and amortization including contract acquisition costs			2,371			5.1	%			2,361			4,732
Stock-based compensation			(19	)		0.0	%			1,636			1,617
ERP implementation cost			-			0.0	%			1,456			1,456
Legal - Lutronic expense			-			0.0	%			561			561
Severance			151			0.3	%			191			342
Board of Directors legal and advisory fees			-			0.0	%			1,280			1,280
Other adjustments			-			0.0	%			97			97
Total adjustments			2,503			5.4	%			7,582			10,085
Non-GAAP		$	8,960			19.3	%		$	39,822		$	(30,862	)

Nine Months Ended September 30, 2024		Gross Profit			Gross Margin			Operating Expenses				Operating Income
Reported		$	21,876		20.7	%		$	99,329			$	(77,453	)
Adjustments:
Depreciation and amortization including contract acquisition costs			5,564		5.3	%			3,782				9,346
Stock-based compensation			395		0.4	%			5,148				5,543
Legal - Lutronic settlement			-		0.0	%			(5,750	)			(5,750	)
Severance			285		0.3	%			1,257				1,542
Gain on early termination of distribution agreement			-		0.0	%			(9,708	)			(9,708	)
Other adjustments			-		0.0	%			263				263
Total adjustments			6,244		5.9	%			(5,008	)			1,236
Non-GAAP		$	28,120		26.6	%		$	104,337			$	(76,217	)
Nine Months Ended September 30, 2023		Gross Profit			Gross Margin			Operating Expenses				Operating Income
Reported		$	54,172		33.3	%		$	152,883			$	(98,711	)
Adjustments:
Depreciation and amortization including contract acquisition costs			5,968		3.7	%			6,342				12,310
Stock-based compensation			706		0.4	%			5,847				6,553
ERP implementation cost			-		0.0	%			2,744				2,744
Legal - Lutronic expense			-		0.0	%			1,607				1,607
Severance			270		0.2	%			621				891
Board of Directors legal and advisory fees			-		0.0	%			8,989				8,989
Other adjustments			307		0.2	%			682				989
Total adjustments			7,251		4.5	%			26,832				34,083
Non-GAAP		$	61,423		37.7	%		$	126,051			$	(64,628	)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241107740612/en/

Cutera Investor Relations Contact:

Shelby Eckerman, VP, Finance

IR@Cutera.com

Source: Cutera, Inc.

FAQ

What was Cutera's (CUTR) revenue in Q3 2024?

Cutera reported Q3 2024 revenue of $32.5 million, representing a 30% decrease compared to Q3 2023.

How much did AviClear sales grow for Cutera (CUTR) in Q3 2024?

AviClear showed 16% growth year-over-year, driven by international capital system sales.

What is Cutera's (CUTR) full-year 2024 revenue guidance?

Cutera maintained its full-year 2024 revenue guidance of $140 million to $145 million.

What was Cutera's (CUTR) cash position at the end of Q3 2024?

Cutera reported cash, cash equivalents, and restricted cash of $59.0 million as of September 30, 2024.